Literature DB >> 20838003

Dose-dependent reduction in pulmonary vascular resistance with epoprostenol in pulmonary arterial hypertension.

Satoshi Homma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20838003     DOI： 10.1253/circj.cj-10-0854

Source DB:  PubMed          Journal:  Circ J        ISSN： 1346-9843            Impact factor:   2.993


× No keyword cloud information.
  3 in total

1.  Prostacyclin-analog therapy in sickle cell pulmonary hypertension.

Authors:  Nargues A Weir; Rehan Saiyed; Shoaib Alam; Anna Conrey; Himanshu D Desai; M Patricia George; Jennifer H Keeley; Elizabeth S Klings; Alem Mehari; James G Taylor; Caterina P Minniti; Gregory J Kato
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

2.  Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.

Authors:  Kelly Marie Chin; Rosechelle Ruggiero; Sonja Bartolome; Mariella Velez-Martinez; Konstantina Darsaklis; Martha Kingman; Scarlet Harden; Fernando Torres
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

3.  Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.

Authors:  Mai Kimura; Yuichi Tamura; Makoto Takei; Tsunehisa Yamamoto; Tomohiko Ono; Masataka Kuwana; Keiichi Fukuda; Toru Satoh
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.